Roche Holding AG’s RHHBY subsidiary Genentech announced that the FDA has approvedan alternative delivery option for itsrheumatoid arthritis drug Actemra. Asubcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) for patients two years or older has been approved by the FDA.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться